Sera Prognostics

Sera Prognostics is a United States-based company located in Salt Lake City, Utah. The company employs 72 people and generates approximately $50 million in annual revenue. Sera Prognostics is a proteomic and bioinformatics company focused on improving pregnancy care through precision biomarker-based tests. The company's flagship product, the PreTRM® Test, provides physicians with individualized risk assessments for premature birth, allowing for earlier proactive interventions in patients deemed higher risk. Sera Prognostics is also actively developing additional tests targeting other pregnancy complications, such as preeclampsia, gestational diabetes, and growth restriction. Sera Prognostics differentiates itself through its commitment to delivering early, actionable insights to physicians, empowering them to enhance patient health outcomes and potentially reduce healthcare costs. Their focus on precision biomarker-based testing aims to revolutionize pregnancy care by providing personalized risk assessments and facilitating timely interventions. For more information about Sera Prognostics, including its values, culture, and career opportunities, please visit www.seraprognostics.com.